givix vet 150 mg purutabletti
ceva santÉ animale - clindamycin hydrochloride - purutabletti - 150 mg - klindamysiini
givix vet 88 mg purutabletti
ceva santÉ animale - clindamycin hydrochloride - purutabletti - 88 mg - klindamysiini
buprefelican vet 0.3 mg/ml injektioneste, liuos
le vet. beheer b.v. - buprenorphine hydrochloride - injektioneste, liuos - 0.3 mg/ml - buprenorfiini
nocdurna 25 mikrog tabletti, kylmäkuivattu
ferring lÄÄkkeet oy - desmopressin acetate - tabletti, kylmäkuivattu - 25 mikrog - desmopressiini
nocdurna 50 mikrog tabletti, kylmäkuivattu
ferring lÄÄkkeet oy - desmopressin acetate - tabletti, kylmäkuivattu - 50 mikrog - desmopressiini
betahistine stada 8 mg tabletti
stada arzneimittel ag - betahistine dihydrochloride - tabletti - 8 mg - betahistiini
betahistine stada 16 mg tabletti
stada arzneimittel ag - betahistine dihydrochloride - tabletti - 16 mg - betahistiini
betahistine stada 24 mg tabletti
stada arzneimittel ag - betahistine dihydrochloride - tabletti - 24 mg - betahistiini
dexketoprofen krka 50 mg / 2 ml injektio-/infuusioneste, liuos
krka, d.d., novo mesto - dexketoprofen trometamol - injektio-/infuusioneste, liuos - 50 mg / 2 ml - deksketoprofeeni
sarclisa
sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastiset aineet - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.